Infinium Pharmachem H1 Revenue Reaches ₹112.01 Crore

Infinium Pharmachem Limited reported standalone revenue from operations of ₹112.01 crore for the half year ended September 30, 2026, and its board approved the unaudited standalone and consolidated financial results on November 6, 2026. The update provides investors with the company’s first reported operating figure for the new financial year.

What did Infinium Pharmachem report for September 2026?

Infinium Pharmachem reported standalone revenue from operations of ₹112.01 crore for the half year ended September 30, 2026. The figure was disclosed in the company’s statement of standalone financial results submitted to the exchange after the board meeting.

The board considered and approved unaudited financial results for both the standalone business and the consolidated group for the half-year period. The filings were accompanied by limited review reports issued by the company’s auditors, as required for the reported interim results.

The available disclosure specifically identifies the ₹112.01 crore revenue figure as standalone revenue from operations. Investors should therefore distinguish it from consolidated income, which includes results of entities covered under consolidation and is presented separately in the company’s complete consolidated financial statement.

The half-year update follows Infinium Pharmachem’s earlier disclosure that its board would meet on November 6 to consider and approve financial results for the period ended September 30. The approval confirms completion of that process under the company’s exchange disclosure obligations.

When did the board approve the half-year results?

The board of Infinium Pharmachem approved the unaudited results for the half year ended September 30, 2026, at its meeting held on November 6, 2026. The company had informed the exchange in advance that the meeting would consider the half-year financial results.

The filing was made pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. That regulation requires listed companies to submit periodic financial results, along with the relevant review or audit reports, within prescribed timelines.

The company said the board approved consolidated unaudited financial results together with the auditor’s limited review report. It also submitted standalone unaudited results and the corresponding limited review report. A limited review is an interim-period assurance exercise and is distinct from a full-year audit.

The reporting date is important because the release covers the first six months of the financial year ending March 2027. It follows the company’s full-year FY26 results, which covered the year ended March 31, 2026.

How does the September 2026 update compare with recent performance?

Infinium Pharmachem’s recent reported figures show higher annual revenue and profit in FY26 than in FY25. For the year ended March 31, 2026, the company reported sales of ₹189.63 crore, revenue of ₹191.77 crore and net income of ₹12.15 crore.

FY26 sales were up from ₹155.71 crore in FY25, while revenue rose from ₹157.83 crore. Net income increased from ₹8.15 crore in FY25. Basic and diluted earnings per share from continuing operations were ₹7.80 in FY26, compared with ₹5.60 a year earlier.

The company’s half-year consolidated data for the period ended March 2026 showed sales of ₹106 crore, operating profit of ₹11 crore and net profit of ₹8 crore. Operating profit margin was 11%, while earnings per share stood at ₹4.20 for that reported half-year period.

For the half year ended September 2025, the same consolidated data set showed sales of ₹84 crore, operating profit of ₹10 crore and net profit of ₹7 crore. These historical numbers provide context, but they should not be directly compared with the newly disclosed ₹112.01 crore figure without accounting for the distinction between standalone and consolidated reporting.

Why do standalone and consolidated figures matter to investors?

Standalone and consolidated results measure different reporting scopes. Standalone accounts reflect the financial performance of Infinium Pharmachem as an individual legal entity, while consolidated accounts combine the parent company with entities required to be included under accounting rules.

This distinction matters when assessing revenue trends, margins, profit and earnings per share. A standalone revenue number should be compared with standalone historical numbers, while a consolidated number should be compared with consolidated historical results. Mixing the two can lead to an inaccurate view of growth or operating performance.

The company’s filing confirms that both sets of September 2026 interim results were approved, but the provided extract gives the detailed revenue-from-operations line only for the standalone statement. It does not provide enough information to calculate consolidated revenue growth, net profit growth or margins for the latest six-month period.

Investors also need to consider that the FY26 annual figures and the historical half-year table may use different labels, including sales, revenue and total income. Each metric has a specific meaning under the financial statements and should be read alongside its notes and comparative period figures.

What is the market relevance of the results disclosure?

The announcement gives the market a current operating data point after Infinium Pharmachem recorded annual revenue of ₹191.77 crore and net profit of ₹12.15 crore in FY26. The standalone revenue figure of ₹112.01 crore for the September 2026 half year indicates the scale of business reported in the first half, but does not by itself establish consolidated profitability or a full-year trend.

For shareholders, the limited review reports add an element of external review to the interim disclosures. The board approval and submission under SEBI LODR also meet the listed company’s periodic reporting requirements, giving investors access to the latest approved half-year financial statements.

The chemical sector can be influenced by product demand, raw-material costs, pricing, financing costs and export conditions. However, the supplied release does not attribute the reported revenue to any particular operational or market factor. It also does not disclose a forward revenue target, margin target, capital expenditure plan or management outlook.

The next useful comparison will be the detailed line-by-line financial statements and subsequent disclosures that allow a like-for-like assessment of standalone and consolidated results. Until then, the confirmed facts are the board’s approval, the limited review process and the reported standalone revenue from operations.

Conclusion

Infinium Pharmachem has completed its September 2026 half-year reporting process, with its board approving unaudited standalone and consolidated results on November 6. The disclosed standalone revenue from operations was ₹112.01 crore, following FY26 total income of ₹191.77 crore and net profit of ₹12.15 crore.

Investors should watch for the full comparative details in the financial statements, particularly consolidated revenue, profit, margins and cash-flow information for the September 2026 half year. The supplied disclosure does not provide a management forecast or a specified next operating target.